These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Causal therapy possibilities in HIV infections]. Baumgarten R Dermatol Monatsschr; 1989; 175(8):469-73. PubMed ID: 2676627 [TBL] [Abstract][Full Text] [Related]
3. [AIDS. Therapeutic approaches in the control of HIV infection]. Müller WE; Schröder HC Med Monatsschr Pharm; 1990 May; 13(5):141-6. PubMed ID: 2192245 [No Abstract] [Full Text] [Related]
5. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406 [TBL] [Abstract][Full Text] [Related]
6. Protease inhibitors: implications for HIV research and treatment. Churchill SA J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):13-8. PubMed ID: 11363325 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle. De Clercq E Biomed Pharmacother; 1996; 50(5):207-15. PubMed ID: 8949401 [TBL] [Abstract][Full Text] [Related]
9. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247 [TBL] [Abstract][Full Text] [Related]
10. Long-term remission of HIV-associated thrombocytopenia parallels ongoing suppression of viral replication. Zell SC; Peterson K West J Med; 1997 Dec; 167(6):433-5. PubMed ID: 9426488 [No Abstract] [Full Text] [Related]
11. When HAART is not enough. Gilden D GMHC Treat Issues; 1996 Oct; 10(10):1-6. PubMed ID: 11364005 [TBL] [Abstract][Full Text] [Related]
12. [Anti-HIV drugs work rapidly or not at all. Virus dynamics--therapeutic consequences]. Aulehla S Fortschr Med; 1995 Apr; 113(12):14-6. PubMed ID: 7789929 [No Abstract] [Full Text] [Related]
13. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. Vella S J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S58-61. PubMed ID: 8595511 [TBL] [Abstract][Full Text] [Related]
14. [Which is the strategy? The latest in the use of antiretrovirals]. Agosto M Sidahora; 1995; ():33-4. PubMed ID: 11363205 [TBL] [Abstract][Full Text] [Related]
15. Saquinavir in the management of HIV infection. Moyle G Br J Hosp Med; 1997 Jun 4-17; 57(11):560-4. PubMed ID: 9307673 [TBL] [Abstract][Full Text] [Related]
16. [[ABC of the antivirals] Project Inform]. Sidahora; 1996; ():19-32. PubMed ID: 11364292 [TBL] [Abstract][Full Text] [Related]
18. Significant inhibitory effects of Hybridon's antisense compound on various HIV-1 replication steps in in vitro tests. AIDS Patient Care STDS; 1996 Dec; 10(6):375-6. PubMed ID: 11361558 [No Abstract] [Full Text] [Related]
19. [Without pharmacology nearly nothing can be accomplished in HIV medicine. Anti-HIV drugs: on the way to the IQ test!]. MMW Fortschr Med; 2001 Apr; 143 Suppl 1():101-2. PubMed ID: 11373759 [No Abstract] [Full Text] [Related]
20. [Chemotherapeutic possibilities in HIV infection]. Vogt MW; Lüthy R; Siegenthaler W Verh Dtsch Ges Inn Med; 1988; 94():531-6. PubMed ID: 3061229 [No Abstract] [Full Text] [Related] [Next] [New Search]